These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 30975955)
1. Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: Single-centre study of Nigerian men. Bello JO; Olanipekun OO; Babata AL Niger J Clin Pract; 2019 Apr; 22(4):511-515. PubMed ID: 30975955 [TBL] [Abstract][Full Text] [Related]
2. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682 [TBL] [Abstract][Full Text] [Related]
3. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213 [TBL] [Abstract][Full Text] [Related]
4. Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China. Jiang ZG; Liao SG Medicine (Baltimore); 2021 Oct; 100(39):e27361. PubMed ID: 34596147 [TBL] [Abstract][Full Text] [Related]
5. The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. Tatenuma T; Kawahara T; Hayashi N; Hasumi H; Makiyama K; Nakaigawa N; Kishida T; Miyoshi Y; Yao M; Uemura H Biomed Res Int; 2019; 2019():2535270. PubMed ID: 31781602 [TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151 [TBL] [Abstract][Full Text] [Related]
7. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012 [TBL] [Abstract][Full Text] [Related]
8. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. Koo KC; Lee JS; Ha JS; Han KS; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH World J Urol; 2019 Nov; 37(11):2375-2384. PubMed ID: 30734074 [TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy. Uemura K; Kawahara T; Yamashita D; Jikuya R; Abe K; Tatenuma T; Yokomizo Y; Izumi K; Teranishi JI; Makiyama K; Yumura Y; Kishida T; Udagawa K; Kobayashi K; Miyoshi Y; Yao M; Uemura H Biomed Res Int; 2017; 2017():7538647. PubMed ID: 28948170 [TBL] [Abstract][Full Text] [Related]
10. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772 [TBL] [Abstract][Full Text] [Related]
11. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664 [TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399 [TBL] [Abstract][Full Text] [Related]
13. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172 [TBL] [Abstract][Full Text] [Related]
14. Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel. Shi X; Fan J; Pei X; Wang Y; Guo G; Yang T; Wang X; He D; Li L Andrologia; 2021 Jul; 53(6):e14064. PubMed ID: 33900646 [TBL] [Abstract][Full Text] [Related]
15. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815 [TBL] [Abstract][Full Text] [Related]
16. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304 [TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657 [TBL] [Abstract][Full Text] [Related]
18. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. Conteduca V; Crabb SJ; Jones RJ; Caffo O; Elliott T; Scarpi E; Fabbri P; Derosa L; Massari F; Numico G; Zarif S; Hanna C; Maines F; Joyce H; Lolli C; De Giorgi U PLoS One; 2016; 11(7):e0158952. PubMed ID: 27434372 [TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Sümbül AT; Sezer A; Abalı H; Köse F; Gültepe I; Mertsoylu H; Muallaoğlu S; Özyılkan Ö Int Urol Nephrol; 2014 Aug; 46(8):1531-5. PubMed ID: 24526335 [TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel. Man YN; Chen YF Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]